您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Berberine chloride hydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Berberine chloride hydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Berberine chloride hydrate图片
CAS NO:68030-18-2
规格:98%
分子量:389.83
包装与价格:
包装价格(元)
10g电议
50g电议
5g电议

产品介绍
Berberine chloride hydrate 是从中草药黄连中分离出来的一种生物碱,常用作抗生素。Berberine chloride hydrate 诱导活性氧 (ROS) 生成并抑制 DNA 拓扑异构酶 (topoisomerase)。抗肿瘤特性。
CAS:68030-18-2
分子式:C20H20ClNO5
分子量:389.83
纯度:98%
存储:Store at -20°C

Background:

Berberine chloride hydrate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1]. ROS[1]DNA topoisomerase[1]


Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29[1]. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth[1]. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase[1].Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM[1]. Cell Proliferation Assay[1] Cell Line: Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29


Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice[1]. Animal Model: 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts[1]


[1]. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62.